Allurion Technology吸引金融分析员买入评级,Roth MKM为2美元,Chardan Capital为2.50美元。 Allurion Technologies attracts buy ratings from financial analysts, with Roth MKM at $2.00 and Chardan Capital at $2.50.

专注于肥胖解决方案的Allurion Technologies (NYSE:ALUR) 已经引起了金融分析师的注意. Allurion Technologies (NYSE: ALUR), which focuses on obesity solutions, has attracted attention from financial analysts. Roth MKM以购买评级和2.00美元的价格目标启动了保险范围,而Chardan Capital则将其目标从5.00美元降至2.50美元,但保持了购买评级。 Roth MKM initiated coverage with a buy rating and a $2.00 price target, while Chardan Capital lowered its target from $5.00 to $2.50 but maintained a buy rating. 该公司报告,每股收入为1美元,收入为1 177万美元。 The company reported earnings of $0.01 per share and revenue of $11.77 million. 机构投资者持有约21.39%的股票。 Institutional investors hold about 21.39% of its stock.